Innate Pharma SA
Innate Pharma SA is a Healthcare company operating in Biotechnology with a $170.9M market cap.
Most recent earnings call: Q1 FY26 on May 13, 2026.
20 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Spoken Alpha tracks IPHA's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 60% positive reaction rate
SamplePeers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IPHA.
$ curl https://api.spokenalpha.com/v1/companies/IPHAFAQ
Spoken Alpha indexes IPHA's earnings call transcripts at https://spokenalpha.com/companies/IPHA. Each call links to attributed speakers and parsed analyst Q&A.
Innate Pharma SA (IPHA) held its most recent earnings call on 2026-05-13, covering fiscal Q1 2026.
Innate Pharma SA (IPHA) operates in the Healthcare sector (Biotechnology industry).
Consistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.56 | $3.56 | +28.2% | -5.3% | -6.9% |
| Q4 FY2026 | $4.89 | $3.54 | +38.0% | +1.7% | +1.6% |
| Q3 FY2026 | $4.93 | $3.65 | +35.0% | -1.0% | -3.3% |
| Q2 FY2026 | $5.29 | $3.71 | +42.5% | -4.1% | -7.1% |
| Q1 FY2025 | $4.84 | $3.69 | +31.2% | +6.0% | +8.1% |
| Q4 FY2025 |
| $4.90 |
| $3.70 |
| +32.5% |
| -2.4% |
| -1.1% |
| Q3 FY2025 | $5.00 | $3.71 | +34.9% | +3.7% | +5.4% |
| Q2 FY2025 | $4.73 | $3.63 | +30.4% | +0.4% | +0.4% |
| Q1 FY2024 | $5.40 | $3.85 | +40.2% | +4.2% | +2.3% |
| Q4 FY2024 | $4.96 | $3.88 | +27.8% | +2.5% | +4.3% |